Introduction
Methods
Participants
Data extracted from EHR
Statistical analysis
Results
Final cohort and measurements for analysis
Characteristic | Group | Statin user | Never-statin user | All |
---|---|---|---|---|
Sex | Female | 29,356 | 22,125 | 51,481 |
Male | 15,117 | 20,553 | 35,670 | |
All | 44,473 | 42,678 | 87,151 | |
Race/ethnicity | African American | 1221 | 1472 | 2693 |
East Asian | 3551 | 2853 | 6404 | |
Latino/Hispanic | 3901 | 3324 | 7225 | |
South Asian | 220 | 180 | 400 | |
White | 35,580 | 34,849 | 70,429 | |
Age | Start of EHR | 55.96 (49.27–63.6) | 47.27 (38.29–56.42) | 52.05 (43.44–60.7) |
End of EHR | 75.39 (68.67–82.66) | 65.95 (56.88–75.33) | 71.18 (62.35–79.91) | |
Length of EHR | 20.7 (17.55–20.72) | 20.38 (15.8–20.72) | 20.63 (16.63–20.72) |
Trait | Group | Number of subjects | Number of FG measures | FG level (median mg/dl ± IQR) | Age at time of FG measure (median ± IQR) |
---|---|---|---|---|---|
Sex | All | 87,151 | 593,130 | 97 ± 16 | 64.5 ± 15.9 |
Female | 51,481 | 325,084 | 95 ± 14 | 63.6 ± 16.3 | |
Male | 35,670 | 268,046 | 99 ± 18 | 65.4 ± 15.3 | |
Age | [21,40] | 8294 | 16,811 | 90 ± 12 | 35.8 ± 6.2 |
(40,50] | 23,247 | 53,946 | 93 ± 13 | 46.4 ± 4.6 | |
(50,60] | 44,328 | 139,694 | 96 ± 16 | 55.8 ± 4.8 | |
(60,70] | 49,487 | 196,287 | 98 ± 16 | 65.1 ± 4.9 | |
(70,80] | 32,416 | 140,695 | 99 ± 16 | 74.2 ± 4.8 | |
(80,90] | 12,012 | 45,697 | 99 ± 17 | 83.1 ± 3.9 | |
Race/ethnicity | African American | 2693 | 18,511 | 97 ± 21 | 61.7 ± 15.7 |
East Asian | 6404 | 47,561 | 98 ± 17 | 60.9 ± 16.8 | |
Latino Hispanic | 7225 | 47,719 | 98 ± 18 | 60.6 ± 17.5 | |
South Asian | 400 | 3017 | 99 ± 21 | 57.3 ± 18 | |
White | 70,429 | 476,322 | 97 ± 16 | 65.3 ± 15.4 | |
Statin user | Never | 44,473 | 245,340 | 94 ± 12 | 61.5 ± 17.6 |
Before | 39,552 | 160,055 | 98 ± 17 | 63.0 ± 13.9 | |
During | 35,332 | 187,735 | 101 ± 22 | 68.9 ± 13.9 |
Comparison of “Never Statin”, “Before Statin” and “During Statin” FG measures
Association of FG with duration of statin exposure based on all statin users
Filter | Univariate model | Multivariate model | ||||||
---|---|---|---|---|---|---|---|---|
Cumulative supply | Cumulative dose | Cumulative supply | Cumulative dose | |||||
Regress coeff (s.e.) | p-value (R2) | Regress coeff (s.e.) | p-value (R2) | Regress coeff (s.e.) | p-value (R2) | Regress coeff (s.e.) | p-value (R2) | |
None n = 157,381 | 0.00373 (0.00041) | 2.47E−19 (0.0005) | 0.00214 (0.00031) | 9.44E−12 (0.0003) | 0.00323 (0.00053) | 1.49E−09 (0.0005) | 0.00060 (0.00041) | 1.41E−01 (0.0005) |
Diabetic n = 137,629 | 0.00523 (0.00041) | 4.20E−37 (0.0012) | 0.00296 (0.00032) | 1.29E−20 (0.0006) | 0.00468 (0.00053) | 1.06E−18 (0.0012) | 0.00067 (0.00041) | 1.04E−01 (0.0012) |
Other n = 121,015 | 0.00392 (0.00046) | 1.42E−17 (0.0006) | 0.00243 (0.00036) | 1.24E−11 (0.0004) | 0.00326 (0.00060) | 4.55E−08 (0.0006) | 0.00081 (0.00047) | 8.39E−02 (0.0006) |
All n = 106,913 | 0.00512 (0.00046) | 5.38E−29 (0.0012) | 0.00324 (0.00037) | 9.66E−19 (0.00070) | 0.00428 (0.00060) | 6.64E−13 (0.0012) | 0.00105 (0.00048) | 2.70E−02 (0.0012) |
Association of FG with statin exposure in two subgroups of statin users
Prior FG | Statin Type | Number of individuals | Number of observations | Regress coeff (S.E.) | p-value (R2) |
---|---|---|---|---|---|
All | All | 25,134 | 106,913 | 0.00512 (0.00046) | 5.38E−29 (0.0012) |
Simva | 8166 | 31,681 | 0.00546 (0.00108) | 4.04E−07 (0.0008) | |
Lova | 14,327 | 69,222 | 0.00463 (0.00053) | 4.88E−18 (0.0011) | |
Atorva | 2339 | 5231 | 0.00656 (0.00327) | 4.52E−02 (0.0008) | |
Normal (< 100) | All | 11,496 | 49,415 | 0.00976 (0.00069) | 2.19E−45 (0.0040) |
Simva | 3765 | 14,471 | 0.00908 (0.00168) | 7.21E−08 (0.0020) | |
Lova | 6542 | 32,309 | 0.00883 (0.00080) | 2.43E−28 (0.0038) | |
Atorva | 1051 | 2280 | 0.01245 (0.00485) | 1.02E−02 (0.0029) |
Association of FG measures with statin exposure measures for different statin types
Statin type | Number of individuals | Number of observations | Regression coefficient (S.E.) | R2 |
---|---|---|---|---|
All | 11,496 | 49,415 | 0.135 (0.00954) | 0.00403 |
Simva | 3765 | 14,471 | 0.126 (0.02234) | 0.00221 |
Lova | 6542 | 32,309 | 0.122 (0.01111) | 0.00371 |
Atorva | 1051 | 2280 | 0.181 (0.08167) | 0.00215 |